Finally, in contrast to the yeast system, we made the surprising observation that inhibition of SRPK1 enhanced sensitivity to cDDP treatment, suggesting that SRPK1 may be a target for therapy of ovarian cancer. Here, SRPK1 is linked to ovarian carcinoma.